Lilly Expands Bispecific Antibody Pact with China’s Innovent BiologicsBy
Eli Lilly and Company and Innovent Biologics, Inc., a Chinese biopharmaceutical company, have expanded their drug development collaboration The companies will collaborate to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outsde of China.
Under the previous agreement, Lilly will exercise its rights to develop, manufacture, and commercialize these potential cancer treatments outside of China.
Innovent will now have the rights to develop, manufacture, and commercialize these potential cancer treatments for China, subject to a Lilly opt-in right for co-development and commercialization. Under the terms of the expanded agreement, Innovent could receive additional milestones totaling more than $1 billion if the products reach certain development, regulatory and sales milestones, both inside and outside of China. Sales royalties and other payments would occur on certain products if commercialized outside China. Further financial terms were not disclosed.
Lilly will create the three preclinical anti-PD-1 based bispecific antibodies using an antibody sequence contributed by Innovent.
Source: Eli Lilly and Company